Veterinary Medicines

Felinta 15 mg prolonged-release tablets for cats

Authorised
  • Carbimazole
Download as PDF

Product identification

Medicine name:
Felinta 15 mg prolonged-release tablets for cats
FELINTA 15 MG COMPRIMES A LIBERATION PROLONGEE POUR CHATS
Active substance:
  • Carbimazole
Target species:
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Carbimazole
    15.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Prolonged-release tablet
Withdrawal period by route of administration:
  • Oral use
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QH03BB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:
  • (ID2) 100 Prolonged-release tablet: Box (Cardboard) with 10 Blister (PolyVinyl Chloride; Aluminium; Orientated PolyAmide) each with 10 Prolonged-release tablet, closed with Foil (Aluminium)
  • (ID1) 30 Prolonged-release tablet: Box (Cardboard) with 3 Blister (PolyVinyl Chloride; Aluminium; Orientated PolyAmide) each with 10 Prolonged-release tablet, closed with Foil (Aluminium)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Billev Pharma East registration of medicines Ltd.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Tiofarma B.V.
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/7352311 6/2022
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0341/002
Concerned member states:
  • France

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 9/04/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."